Yes DMX700 for COPD.
DMX200 was assessed for covid but that was tap on the shoulder from other agencies and DXB had no involvement in the running or funding of those trials (other than manufacture the doses for the trials).
DKD was unsuccessful because the trial design was only 12 weeks and did not allow sufficient time for proteinuria levels to fall except in late-stage patients which were not the target of the study. Unsuccessful but enough of an outcome to warrant the phase 3 trial that ACADI were going to lead. We have no information on why this has since stalled, however we know that DXB have been 99% focused on FSGS and it appears for good reason.
Ann: Dimerix Presents at ASX Small & Mid-Cap Conference, page-34
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.0¢ |
Change
0.040(8.89%) |
Mkt cap ! $269.6M | |||
| Open | High | Low | Value | Volume |
| 46.0¢ | 50.5¢ | 46.0¢ | $2.255M | 4.621M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 49.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.5¢ | 21052 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |